Media statement released, 22 August 2014:

PBAC decisions – a mixed bag for Australians living with Hepatitis C

simeprevir (Olysio)
Hepatitis Australia today welcomed the recommendation to add simeprevir (Olysio) to the Pharmaceutical Benefits Scheme (PBS) for the treatment of genotype 1 chronic hepatitis C.

sofosbuvir (Sovaldi)
Responding to the PBAC decision to reject an application to subsidise the antiviral medication sofosbuvir (Sovaldi), Ms Tyrrell said “it’s a sad day when access to game-changing therapy is denied. This is a bad outcome for people living with hepatitis C”. Read more - Download now. (PDF 245.43kb)

 

HCV Quest for People Living with Hepatitis C

A global patient survey which will reveal how HCV is treated around the world has been developed by the World Hepatitis Alliance.

If you are living with hepatitis C, please take a moment to complete this survey. By doing so, you will help to inform international policy makers, opinion-leading doctors and the pharmaceutical companies who develop the treatments about what it is really like to live with hepatitis C. 

For more information and to participate click here.

 

World Hepatitis Day, 28 July 

The World Hepatitis Alliance first coordinated World Hepatitis Day in 2008 in response to the concern that chronic viral hepatitis did not have the level of awareness, nor the political priority, seen with other communicable diseases such as HIV/AIDS, tuberculosis and malaria.

In 2010 the World Health Assembly endorsed July 28 as World Hepatitis Day and it became one of only four ‘World Health Days’ recognised by the World Health Organization.

At the global level, the World Hepatitis Alliance works in conjunction with the World Health Organization to coordinate World Hepatitis Day. Each year, July 28 provides a focus for individuals, community groups, clinicians and other supporters to run awareness-raising events. The thousands of events which take place each year help to raise awareness and influence action on viral hepatitis at both a local and a global level

Almost half a million Australians are now living with chronic hepatitis B and C. This year in Australia we want to highlight the importance of regular liver check-ups and push for the changes needed within the health system to ensure all people living with, hepatitis B and hepatitis C have access to regular liver check-ups as a standard part of their care plan.

To find out what is happening in Australia on World Hepatitis Day 2014 Click here 

 

Will PBAC recommend the PBS listing of the latest hepatitis C treatments?

sample pills

sample pills

Hepatitis Australia would like to thank all of the individuals and organisations who recently lodged their comments or submissions with the Pharmaceutical Benefits Advisory Committee (PBAC).

Hepatitis Australia has lodged a submission which can be viewed here.

The approval of the two new drugs (sofosbuvir and simeprevir) will be an important step in the journey to optimal treatment and cure for Australians living with hepatitis C. Hepatitis Australia has called for the new medicines to be available to all people living with hepatitis C and not be restricted to only people with advanced hepatitis C.

Hepatitis Australia will be monitoring for any developments and will advise the outcome of the PBAC decision as soon as it becomes known. If PBAC do recommend PBS listing of the medicines this will not be the end of the process.  The Health Minister (Hon. Peter Dutton) will then consider the recommendation which will likely need be put forward for parliamentary approval. Hepatitis Australia would then be advocating to parliamentarians for the immediate listing of the medicines.

Support Us

You can also donate directly to Hepatitis Australia. Please contribute to our aim of a world without viral hepatitis by making a tax deductible donation. Find out more

Hepatitis Australia is a non-government, not-for-profit organisation that became incorporated in 1997. We do not provide services to individuals. To locate hepatitis services in your area visit the services page or call the Info line on 1300 437 222. Our members consist of the state and territory hepatitis organisations and other key services providing hepatitis services.

 

Page Updated:  15 July 2014

National Information Line

1300 HEP ABC  
(1300 437 222)

Visit Now

Visit Now